Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - albumin, quantity: 12.5 g - injection, intravenous infusion - excipient ingredients: sodium acetyltryptophanate; sodium octanoate; water for injections; sodium chloride - restoration and maintenance of circulating blood volume where volume deficiency has been demonstrated and use of a colloid is appropriate. the choice of albumin rather than artificial colloid will depend on the clinical situation of the individual patient.

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

vetoquinol australia pty ltd - gonadotrophin-serum - parenteral liquid/solution/suspension - gonadotrophin-serum hormone-gonadotrophin active 20000.0 iu/vial - endocrine system - cattle | dog - female (bitch) | goat | pigs | sheep | beef | billy | bitch | boar | bos indicus | bos taurus | bovine | buck | b - anoestrus | increase ovulation rate | induce superovulation | inducing oestrus | lactation anoestrus | oestrus induction | prolonged weaning to mating

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

vetoquinol australia pty ltd - gonadotrophin-serum - parenteral liquid/solution/suspension - gonadotrophin-serum hormone-gonadotrophin active 6000.0 iu/vial - endocrine system - cattle | dog - female (bitch) | goat | pigs | sheep | beef | billy | bitch | boar | bos indicus | bos taurus | bovine | buck | b - anoestrus | increase ovulation rate | induce superovulation | inducing oestrus | lactation anoestrus | oestrus induction | prolonged weaning to mating

United States - English - NLM (National Library of Medicine)

washington homeopathic products - serum anguillae - to relieve the symptoms of dreams of snakes. indications:  serum anguillae   dreams of snakes if symptoms persist/worsen or if pregnant/nursing, consult your practitioner.

United States - English - NLM (National Library of Medicine)

washington homeopathic products - serum anguillae - to relieve the symptoms of dreams of snakes. indications: serum anguillae   dreams of snakes if symptoms persist/worsen or if pregnant/nursing, stop use and consult your practitioner.

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

alfa pharmaceuticals limited, tanzania - sodium chloride & glucose intravenous infusion bp (0.9% w/v & 5% w/v) - intravenous infusion - 0.9% & 5%

European Union - English - EMA (European Medicines Agency)

merck sharp & dohme b.v. - interferon alfa-2b - carcinoid tumor; leukemia, hairy cell; lymphoma, follicular; hepatitis b, chronic; hepatitis c, chronic; leukemia, myelogenous, chronic, bcr-abl positive; melanoma; multiple myeloma - immunostimulants, - chronic hepatitis btreatment of adult patients with chronic hepatitis b associated with evidence of hepatitis-b viral replication (presence of dna of hepatitis-b virus (hbv-dna) and hepatitis-b antigen (hbeag), elevated alanine aminotransferase (alt) and histologically proven active liver inflammation and / or fibrosis.chronic hepatitis cbefore initiating treatment with introna, consideration should be given to the results from clinical trials comparing introna with pegylated interferon.adult patientsintrona is indicated for the treatment of adult patients with chronic hepatitis c who have elevated transaminases without liver decompensation and who are positive for hepatitis-c virus-rna (hcv-rna).the best way to use introna in this indication is in combination with ribavirin.children three years of age and older and adolescentsintrona is indicated, in a combination regimen with ribavirin, for the treatment of children three years of age and older and adolescents, who have chronic hepatitis c, not previously treated, without liver decompensation, and who are positive for hcv-rna. when deciding not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition that resulted in reduced final adult height in some patients.the decision to treat should be made on a case-by-case basis.hairy-cell leukaemiatreatment of patients with hairy cell leukaemia.chronic myelogenous leukaemiamonotherapytreatment of adult patients with philadelphia-chromosome- or bcr/abl-translocation-positive chronic myelogenous leukaemia.clinical experience indicates that a haematological and cytogenetic major / minor response is obtainable in the majority of patients treated. a major cytogenetic response is defined by < 34 % ph+ leukaemic cells in the bone marrow, whereas a minor response is ≥ 34 %, but < 90 % ph+ cells in the marrow.combination therapythe combination of interferon alfa-2b and cytarabine (ara-c) administered during the first 12 months of treatment has been demonstrated to significantly increase the rate of major cytogenetic responses and to significantly prolong the overall survival at three years when compared to interferon alfa-2b monotherapy.multiple myelomaas maintenance therapy in patients who have achieved objective remission (more than 50% reduction in myeloma protein) following initial induction chemotherapy.current clinical experience indicates that maintenance therapy with interferon alfa-2b prolongs the plateau phase; however, effects on overall survival have not been conclusively demonstrated.follicular lymphomatreatment of high-tumour-burden follicular lymphoma as adjunct to appropriate combination induction chemotherapy such as a chop-like regimen. high tumour burden is defined as having at least one of the following: bulky tumour mass (> 7 cm), involvement of three or more nodal sites (each > 3 cm), systemic symptoms (weight loss > 10 %, pyrexia > 38°c for more than eight days, or nocturnal sweats), splenomegaly beyond the umbilicus, major organ obstruction or compression syndrome, orbital or epidural involvement, serous effusion, or leukaemia.carcinoid tumourtreatment of carcinoid tumours with lymph node or liver metastases and with 'carcinoid syndrome'.malignant melanomaas adjuvant therapy in patients who are free of disease after surgery but are at high risk of systemic recurrence, e.g. patients with primary or recurrent (clinical or pathological) lymph-node.

Australia - English - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - amiodarone hydrochloride, quantity: 150 mg - injection, solution - excipient ingredients: polysorbate 80; benzyl alcohol; water for injections - severe cases of tachyarrhythmias (eg. wolff-parkinson-white syndrome, supraventricular, nodal and ventricular tachycardias, atrial flutter and fibrillation, ventricular fibrillation) not responding to other therapy. treatment should be initiated in hospital. it is recommended that the patient should be regularly monitored for possible toxicity (eg. thyroid function, chest x-ray, ophthalmological examination, liver function etc.) during the entire course of therapy and for several months after discontinuation. cordarone x intravenous may be used for treatment initiated in a hospital for severe cases of tachyarrhythmias (atrial, junctional and ventricular) not responding to other therapy and when a rapid response is required. cordarone x intravenous should only be used where facilities exist for cardiac monitoring and defibrillation should the need arise

Australia - English - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - glucose monohydrate, quantity: 54.99 mg/ml (equivalent: glucose, qty 50 mg/ml) - injection, intravenous infusion - excipient ingredients: water for injections; hydrochloric acid; sodium hydroxide - indications as at 31 july 2000: for fluid and carbohydrate depletion wherever a non-electrolyte fluid is required. in the treatment of hypoglycaemia. in the treatment of acute diarrhoeal disease. as a vehicle for the administration of other medications.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - olive oil, quantity: 50 g; fish oil - rich in omega-3 acids, quantity: 30 g; medium chain triglycerides, quantity: 60 g; soya oil, quantity: 60 g - injection, intravenous infusion - excipient ingredients: glycerol; sodium oleate; dl-alpha-tocopherol; water for injections; egg lecithin; sodium hydroxide - supply of energy and essential fatty acids to patients, as part of a parenteral nutrition regimen, when oral or enteral nutrition is impossible, insufficient or contra-indicated.